Related Experiment Video

Updated: Jun 22, 2026

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

Lapatinib for inflammatory breast cancer

Peter S Hall, Andrew Hanby, David A Cameron

    The Lancet. Oncology
    |June 2, 2009
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    Single-port Non-liposuction Endoscopic Axillary Lymph Node Dissection in Breast Cancer Surgery
    11:49

    Single-port Non-liposuction Endoscopic Axillary Lymph Node Dissection in Breast Cancer Surgery

    Published on: April 3, 2026

    Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
    11:13

    Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

    Published on: June 9, 2023

    Related Experiment Videos

    Last Updated: Jun 22, 2026

    Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
    09:32

    Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

    Published on: October 17, 2025

    Single-port Non-liposuction Endoscopic Axillary Lymph Node Dissection in Breast Cancer Surgery
    11:49

    Single-port Non-liposuction Endoscopic Axillary Lymph Node Dissection in Breast Cancer Surgery

    Published on: April 3, 2026

    Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
    11:13

    Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

    Published on: June 9, 2023

    Related Concept Videos

    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against specific...

    Articles linked to this work by shared authors, journal, and citation graph.

    Tucatinib in patients with HER2-positive advanced/metastatic breast cancer: A systematic literature review of real-world evidence.

    Breast (Edinburgh, Scotland)·2026

    Mental Health Outcomes Among Long-Term Survivors of Childhood, Adolescent and Young Adult Cancer: A Scottish Population-Based Cohort Study.

    Psycho-oncology·2026

    EBCC-15 manifesto: Removing age-related barriers to improve equity in breast cancer care.

    Breast (Edinburgh, Scotland)·2026

    International disruptions to cancer diagnosis and stage at presentation during the COVID-19 pandemic in 2020: an International Cancer Benchmarking Partnership (ICBP) population-based study.

    The Lancet. Oncology·2026

    Comparing the effectiveness, cost-effectiveness and implementation of low-dose oral modified release morphine in people with chronic breathlessness: a synopsis of a RCT and process evaluation.

    Health technology assessment (Winchester, England)·2026

    Modelled impact of a multi-cancer early detection screening programme on cancer treatment in England.

    British journal of cancer·2026

    Efficacy and safety of dabrafenib plus trametinib in adults with differentiated thyroid cancer: a randomised, double-blind, placebo-controlled, phase 3 trial.

    The Lancet. Oncology·2026

    Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial.

    The Lancet. Oncology·2026

    Single, early intravesical instillation of pirarubicin in the prevention of bladder recurrence after radical nephroureterectomy for upper tract urothelial carcinoma (JCOG1403): a multicentre, open-label, randomised, phase 3 trial.

    The Lancet. Oncology·2026

    Systemic therapy, gastrectomy, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy versus systemic therapy alone for gastric cancer with limited peritoneal metastases (PERISCOPE II): final results of a multicentre, randomised, controlled, phase 3 trial after an unplanned commissioned interim analysis.

    The Lancet. Oncology·2026

    Somatostatin receptor PET response assessment framework for patients with neuroendocrine tumours (V1.0): a modified Delphi consensus from the European Neuroendocrine Tumor Society (endorsed by EANM and NANETS).

    The Lancet. Oncology·2026

    Differential impact of proton pump inhibitors and antibiotics on immunotherapy efficacy after chemoradiotherapy in locally advanced non-small-cell lung cancer: a post-hoc analysis of the PACIFIC trial.

    The Lancet. Oncology·2026

    Tertiary lymphoid structures as biomarkers and therapeutic targets in neoadjuvant cancer immunotherapy.

    Frontiers in immunology·2026

    The hidden tumour: giant anterior mediastinal thymolipoma, an incidental finding.

    Polish journal of pathology : official journal of the Polish Society of Pathologists·2026

    FADS1-mediated Efferocytosis in Tumor-Associated Macrophages Shapes an Immunosuppressive Microenvironment in Gastric Cancer.

    Cellular and molecular life sciences : CMLS·2026

    The tumoural landscape of lymphocytes and immune pathways in immunotherapy-treated melanoma patients.

    Genes and immunity·2026

    Strategic engineering B cell immunity for cancer immunotherapy.

    Journal of controlled release : official journal of the Controlled Release Society·2026

    An Endometrioid Carcinoma With an Adenoma Malignum-like Pattern of Invasion: New Insight into Molecular Features.

    International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us